nodes	percent_of_prediction	percent_of_DWPC	metapath
Pranlukast—TNF—urinary bladder cancer	0.497	1	CbGaD
Pranlukast—ABCC2—Carboplatin—urinary bladder cancer	0.0507	0.188	CbGbCtD
Pranlukast—ABCC2—Cisplatin—urinary bladder cancer	0.0434	0.16	CbGbCtD
Pranlukast—ABCC2—Etoposide—urinary bladder cancer	0.0426	0.158	CbGbCtD
Pranlukast—CYP3A4—Thiotepa—urinary bladder cancer	0.0307	0.114	CbGbCtD
Pranlukast—ABCC2—Doxorubicin—urinary bladder cancer	0.0291	0.108	CbGbCtD
Pranlukast—ABCC2—Methotrexate—urinary bladder cancer	0.0281	0.104	CbGbCtD
Pranlukast—CYP2C9—Fluorouracil—urinary bladder cancer	0.0171	0.0634	CbGbCtD
Pranlukast—CYP2C9—Cisplatin—urinary bladder cancer	0.0146	0.0539	CbGbCtD
Pranlukast—CYP3A4—Etoposide—urinary bladder cancer	0.00832	0.0308	CbGbCtD
Pranlukast—IL5—epithelium—urinary bladder cancer	0.0069	0.0957	CbGeAlD
Pranlukast—CYP3A4—Doxorubicin—urinary bladder cancer	0.00568	0.021	CbGbCtD
Pranlukast—MUC2—epithelium—urinary bladder cancer	0.00531	0.0736	CbGeAlD
Pranlukast—MUC2—renal system—urinary bladder cancer	0.00492	0.0683	CbGeAlD
Pranlukast—NFKB1—prostate gland—urinary bladder cancer	0.00412	0.0571	CbGeAlD
Pranlukast—CYSLTR1—prostate gland—urinary bladder cancer	0.00405	0.0561	CbGeAlD
Pranlukast—MUC2—female reproductive system—urinary bladder cancer	0.00394	0.0547	CbGeAlD
Pranlukast—TNF—vagina—urinary bladder cancer	0.00357	0.0494	CbGeAlD
Pranlukast—NFKB1—seminal vesicle—urinary bladder cancer	0.00348	0.0483	CbGeAlD
Pranlukast—CYP2C9—urine—urinary bladder cancer	0.003	0.0416	CbGeAlD
Pranlukast—IL5—lymph node—urinary bladder cancer	0.003	0.0416	CbGeAlD
Pranlukast—CYSLTR1—smooth muscle tissue—urinary bladder cancer	0.00287	0.0397	CbGeAlD
Pranlukast—NFKB1—renal system—urinary bladder cancer	0.00281	0.0389	CbGeAlD
Pranlukast—NFKB1—urethra—urinary bladder cancer	0.00276	0.0382	CbGeAlD
Pranlukast—TNF—lymph node—urinary bladder cancer	0.00231	0.032	CbGeAlD
Pranlukast—CYP3A4—urine—urinary bladder cancer	0.00229	0.0317	CbGeAlD
Pranlukast—NFKB1—female reproductive system—urinary bladder cancer	0.00225	0.0312	CbGeAlD
Pranlukast—CYSLTR1—female reproductive system—urinary bladder cancer	0.00221	0.0306	CbGeAlD
Pranlukast—NFKB1—vagina—urinary bladder cancer	0.00203	0.0282	CbGeAlD
Pranlukast—CYSLTR1—vagina—urinary bladder cancer	0.002	0.0277	CbGeAlD
Pranlukast—Ospemifene—ESR1—urinary bladder cancer	0.00168	1	CrCbGaD
Pranlukast—ABCC2—prostate gland—urinary bladder cancer	0.00162	0.0224	CbGeAlD
Pranlukast—NFKB1—lymph node—urinary bladder cancer	0.00132	0.0182	CbGeAlD
Pranlukast—CYSLTR1—lymph node—urinary bladder cancer	0.00129	0.0179	CbGeAlD
Pranlukast—ABCC2—renal system—urinary bladder cancer	0.0011	0.0153	CbGeAlD
Pranlukast—ABCC2—female reproductive system—urinary bladder cancer	0.000883	0.0122	CbGeAlD
Pranlukast—CYP2C9—female reproductive system—urinary bladder cancer	0.000588	0.00815	CbGeAlD
Pranlukast—CYP3A4—renal system—urinary bladder cancer	0.00056	0.00776	CbGeAlD
Pranlukast—ABCC2—lymph node—urinary bladder cancer	0.000516	0.00716	CbGeAlD
Pranlukast—CYP3A4—female reproductive system—urinary bladder cancer	0.000449	0.00622	CbGeAlD
Pranlukast—IL5—GPCR downstream signaling—IL2—urinary bladder cancer	4.19e-05	0.000264	CbGpPWpGaD
Pranlukast—NFKB1—MAPK Signaling Pathway—TP53—urinary bladder cancer	4.18e-05	0.000263	CbGpPWpGaD
Pranlukast—NFKB1—B Cell Activation—KRAS—urinary bladder cancer	4.17e-05	0.000263	CbGpPWpGaD
Pranlukast—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	4.15e-05	0.000261	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—RBX1—urinary bladder cancer	4.14e-05	0.000261	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—CDK4—urinary bladder cancer	4.14e-05	0.000261	CbGpPWpGaD
Pranlukast—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	4.09e-05	0.000258	CbGpPWpGaD
Pranlukast—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	4.07e-05	0.000256	CbGpPWpGaD
Pranlukast—IL5—Hemostasis—HRAS—urinary bladder cancer	4.07e-05	0.000256	CbGpPWpGaD
Pranlukast—NFKB1—Cellular responses to stress—EP300—urinary bladder cancer	4.06e-05	0.000256	CbGpPWpGaD
Pranlukast—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—HRAS—urinary bladder cancer	4.01e-05	0.000253	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	4.01e-05	0.000253	CbGpPWpGaD
Pranlukast—NFKB1—Signaling by NGF—CDKN1A—urinary bladder cancer	4.01e-05	0.000253	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—NCOR1—urinary bladder cancer	4e-05	0.000252	CbGpPWpGaD
Pranlukast—NFKB1—Signaling by NGF—PTEN—urinary bladder cancer	4e-05	0.000252	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—CXCL8—urinary bladder cancer	3.98e-05	0.000251	CbGpPWpGaD
Pranlukast—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	3.95e-05	0.000249	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—GLI1—urinary bladder cancer	3.91e-05	0.000246	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	3.9e-05	0.000246	CbGpPWpGaD
Pranlukast—TNF—MAPK Signaling Pathway—MYC—urinary bladder cancer	3.87e-05	0.000244	CbGpPWpGaD
Pranlukast—NFKB1—Cellular Senescence—TP53—urinary bladder cancer	3.85e-05	0.000243	CbGpPWpGaD
Pranlukast—IL5—Immune System—ERBB2—urinary bladder cancer	3.83e-05	0.000242	CbGpPWpGaD
Pranlukast—NFKB1—Fc epsilon receptor (FCERI) signaling—HRAS—urinary bladder cancer	3.83e-05	0.000241	CbGpPWpGaD
Pranlukast—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	3.81e-05	0.00024	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—IL2—urinary bladder cancer	3.8e-05	0.00024	CbGpPWpGaD
Pranlukast—TNF—MAPK Signaling Pathway—EGFR—urinary bladder cancer	3.79e-05	0.000239	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—TERT—urinary bladder cancer	3.79e-05	0.000239	CbGpPWpGaD
Pranlukast—NFKB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.77e-05	0.000238	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—PPARG—urinary bladder cancer	3.76e-05	0.000237	CbGpPWpGaD
Pranlukast—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.76e-05	0.000237	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—FGFR3—urinary bladder cancer	3.75e-05	0.000236	CbGpPWpGaD
Pranlukast—NFKB1—Signaling by NGF—SRC—urinary bladder cancer	3.71e-05	0.000234	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—CREBBP—urinary bladder cancer	3.61e-05	0.000228	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—FGFR3—urinary bladder cancer	3.6e-05	0.000227	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR downstream signaling—RHOA—urinary bladder cancer	3.58e-05	0.000226	CbGpPWpGaD
Pranlukast—TNF—MAPK Signaling Pathway—KRAS—urinary bladder cancer	3.58e-05	0.000226	CbGpPWpGaD
Pranlukast—NFKB1—B Cell Activation—HRAS—urinary bladder cancer	3.54e-05	0.000223	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.5e-05	0.00022	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—FGFR3—urinary bladder cancer	3.48e-05	0.000219	CbGpPWpGaD
Pranlukast—IL5—Immune System—IL2—urinary bladder cancer	3.47e-05	0.000219	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—S100B—urinary bladder cancer	3.43e-05	0.000216	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.42e-05	0.000216	CbGpPWpGaD
Pranlukast—TNF—Apoptosis—TP53—urinary bladder cancer	3.39e-05	0.000214	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—ESR1—urinary bladder cancer	3.38e-05	0.000213	CbGpPWpGaD
Pranlukast—IL5—Immune System—CDKN1A—urinary bladder cancer	3.28e-05	0.000206	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—RHOA—urinary bladder cancer	3.27e-05	0.000206	CbGpPWpGaD
Pranlukast—IL5—Immune System—PTEN—urinary bladder cancer	3.27e-05	0.000206	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—RHOA—urinary bladder cancer	3.25e-05	0.000205	CbGpPWpGaD
Pranlukast—NFKB1—Signaling by NGF—EGFR—urinary bladder cancer	3.25e-05	0.000205	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.23e-05	0.000204	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—CREBBP—urinary bladder cancer	3.19e-05	0.000201	CbGpPWpGaD
Pranlukast—TNF—MAPK Signaling Pathway—TP53—urinary bladder cancer	3.18e-05	0.000201	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—IFNA2—urinary bladder cancer	3.18e-05	0.0002	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—CDK4—urinary bladder cancer	3.16e-05	0.000199	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.14e-05	0.000198	CbGpPWpGaD
Pranlukast—NFKB1—Cytokine Signaling in Immune system—KRAS—urinary bladder cancer	3.12e-05	0.000197	CbGpPWpGaD
Pranlukast—IL5—Immune System—EP300—urinary bladder cancer	3.12e-05	0.000196	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—NCOR1—urinary bladder cancer	3.08e-05	0.000194	CbGpPWpGaD
Pranlukast—NFKB1—Signaling by NGF—KRAS—urinary bladder cancer	3.07e-05	0.000194	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—CDH1—urinary bladder cancer	3.04e-05	0.000192	CbGpPWpGaD
Pranlukast—IL5—Immune System—SRC—urinary bladder cancer	3.03e-05	0.000191	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—ERBB2—urinary bladder cancer	3.03e-05	0.000191	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR downstream signaling—IL2—urinary bladder cancer	3e-05	0.000189	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—S100B—urinary bladder cancer	3e-05	0.000189	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—CREBBP—urinary bladder cancer	2.96e-05	0.000187	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—IGF1—urinary bladder cancer	2.92e-05	0.000184	CbGpPWpGaD
Pranlukast—NFKB1—Cellular responses to stress—TP53—urinary bladder cancer	2.91e-05	0.000183	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—EGFR—urinary bladder cancer	2.91e-05	0.000183	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.87e-05	0.000181	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—PPARG—urinary bladder cancer	2.87e-05	0.000181	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—CXCL8—urinary bladder cancer	2.85e-05	0.00018	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—CREBBP—urinary bladder cancer	2.75e-05	0.000174	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—KRAS—urinary bladder cancer	2.75e-05	0.000173	CbGpPWpGaD
Pranlukast—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	2.73e-05	0.000172	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—IL2—urinary bladder cancer	2.73e-05	0.000172	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—TERT—urinary bladder cancer	2.72e-05	0.000171	CbGpPWpGaD
Pranlukast—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	2.7e-05	0.00017	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—RBX1—urinary bladder cancer	2.68e-05	0.000169	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—RHOA—urinary bladder cancer	2.68e-05	0.000169	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—ERBB2—urinary bladder cancer	2.67e-05	0.000169	CbGpPWpGaD
Pranlukast—IL5—Immune System—EGFR—urinary bladder cancer	2.66e-05	0.000167	CbGpPWpGaD
Pranlukast—NFKB1—Cytokine Signaling in Immune system—HRAS—urinary bladder cancer	2.65e-05	0.000167	CbGpPWpGaD
Pranlukast—NFKB1—Signaling by NGF—HRAS—urinary bladder cancer	2.61e-05	0.000164	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—MMP9—urinary bladder cancer	2.6e-05	0.000164	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—ERBB2—urinary bladder cancer	2.57e-05	0.000162	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	2.54e-05	0.00016	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—TSC1—urinary bladder cancer	2.52e-05	0.000159	CbGpPWpGaD
Pranlukast—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	2.51e-05	0.000158	CbGpPWpGaD
Pranlukast—IL5—Immune System—KRAS—urinary bladder cancer	2.51e-05	0.000158	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—FGFR3—urinary bladder cancer	2.49e-05	0.000157	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—RHOA—urinary bladder cancer	2.49e-05	0.000157	CbGpPWpGaD
Pranlukast—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	2.48e-05	0.000156	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—ERBB2—urinary bladder cancer	2.48e-05	0.000156	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—EP300—urinary bladder cancer	2.46e-05	0.000155	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—ESR1—urinary bladder cancer	2.42e-05	0.000153	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	2.41e-05	0.000152	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—NAT1—urinary bladder cancer	2.41e-05	0.000152	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—JAG1—urinary bladder cancer	2.4e-05	0.000151	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—SRC—urinary bladder cancer	2.39e-05	0.000151	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.37e-05	0.000149	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—CXCL8—urinary bladder cancer	2.35e-05	0.000148	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—HRAS—urinary bladder cancer	2.33e-05	0.000147	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—ERBB2—urinary bladder cancer	2.31e-05	0.000145	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—CDKN1A—urinary bladder cancer	2.28e-05	0.000144	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—PTEN—urinary bladder cancer	2.28e-05	0.000144	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—IL2—urinary bladder cancer	2.25e-05	0.000142	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	2.2e-05	0.000139	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—CDKN1A—urinary bladder cancer	2.19e-05	0.000138	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—PTEN—urinary bladder cancer	2.19e-05	0.000138	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—CCND1—urinary bladder cancer	2.19e-05	0.000138	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—FGFR3—urinary bladder cancer	2.18e-05	0.000138	CbGpPWpGaD
Pranlukast—ABCC2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.18e-05	0.000137	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—EP300—urinary bladder cancer	2.17e-05	0.000137	CbGpPWpGaD
Pranlukast—IL5—Immune System—HRAS—urinary bladder cancer	2.13e-05	0.000134	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—MMP9—urinary bladder cancer	2.13e-05	0.000134	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—CREBBP—urinary bladder cancer	2.12e-05	0.000134	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—CDKN1A—urinary bladder cancer	2.12e-05	0.000133	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—SRC—urinary bladder cancer	2.11e-05	0.000133	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—PTEN—urinary bladder cancer	2.11e-05	0.000133	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—EGFR—urinary bladder cancer	2.1e-05	0.000132	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—IGF1—urinary bladder cancer	2.1e-05	0.000132	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—EGFR—urinary bladder cancer	2.09e-05	0.000132	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—SRC—urinary bladder cancer	2.03e-05	0.000128	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—EP300—urinary bladder cancer	2.01e-05	0.000127	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—TNF—urinary bladder cancer	2e-05	0.000126	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	1.98e-05	0.000125	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—KRAS—urinary bladder cancer	1.98e-05	0.000125	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—MMP9—urinary bladder cancer	1.98e-05	0.000125	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—KRAS—urinary bladder cancer	1.97e-05	0.000124	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—SRC—urinary bladder cancer	1.96e-05	0.000124	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—S100B—urinary bladder cancer	1.94e-05	0.000122	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—RHOA—urinary bladder cancer	1.92e-05	0.000121	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—EP300—urinary bladder cancer	1.88e-05	0.000118	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	1.87e-05	0.000118	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—CREBBP—urinary bladder cancer	1.86e-05	0.000117	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—EGFR—urinary bladder cancer	1.85e-05	0.000117	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—CDH1—urinary bladder cancer	1.85e-05	0.000116	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	1.82e-05	0.000115	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—SRC—urinary bladder cancer	1.82e-05	0.000115	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—EGFR—urinary bladder cancer	1.78e-05	0.000112	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—ERBB2—urinary bladder cancer	1.78e-05	0.000112	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—MYC—urinary bladder cancer	1.76e-05	0.000111	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—KRAS—urinary bladder cancer	1.75e-05	0.00011	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—NCOR1—urinary bladder cancer	1.75e-05	0.00011	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—EGFR—urinary bladder cancer	1.72e-05	0.000108	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—CXCL8—urinary bladder cancer	1.69e-05	0.000106	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—HRAS—urinary bladder cancer	1.68e-05	0.000106	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—KRAS—urinary bladder cancer	1.68e-05	0.000106	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—HRAS—urinary bladder cancer	1.68e-05	0.000106	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.68e-05	0.000106	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—KRAS—urinary bladder cancer	1.62e-05	0.000102	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—IL2—urinary bladder cancer	1.61e-05	0.000102	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—EGFR—urinary bladder cancer	1.6e-05	0.000101	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.59e-05	0.0001	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.59e-05	0.0001	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—CCND1—urinary bladder cancer	1.57e-05	9.9e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—ERBB2—urinary bladder cancer	1.56e-05	9.82e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—TERT—urinary bladder cancer	1.54e-05	9.7e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—MMP9—urinary bladder cancer	1.53e-05	9.62e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.52e-05	9.58e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—PTEN—urinary bladder cancer	1.52e-05	9.56e-05	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—KRAS—urinary bladder cancer	1.51e-05	9.52e-05	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—HRAS—urinary bladder cancer	1.49e-05	9.38e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.46e-05	9.22e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—TYMP—urinary bladder cancer	1.46e-05	9.2e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.45e-05	9.16e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—EP300—urinary bladder cancer	1.45e-05	9.12e-05	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—TP53—urinary bladder cancer	1.44e-05	9.09e-05	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—HRAS—urinary bladder cancer	1.43e-05	9.01e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—FGFR3—urinary bladder cancer	1.41e-05	8.9e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—IL2—urinary bladder cancer	1.41e-05	8.9e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—SRC—urinary bladder cancer	1.41e-05	8.87e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.4e-05	8.83e-05	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—HRAS—urinary bladder cancer	1.38e-05	8.69e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—ESR1—urinary bladder cancer	1.37e-05	8.65e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—CDKN1A—urinary bladder cancer	1.33e-05	8.39e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—PTEN—urinary bladder cancer	1.33e-05	8.37e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—NAT2—urinary bladder cancer	1.32e-05	8.32e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.31e-05	8.24e-05	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—HRAS—urinary bladder cancer	1.28e-05	8.09e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—EP300—urinary bladder cancer	1.27e-05	7.98e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—MYC—urinary bladder cancer	1.26e-05	7.94e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.23e-05	7.79e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—EGFR—urinary bladder cancer	1.23e-05	7.77e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—SRC—urinary bladder cancer	1.23e-05	7.76e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.2e-05	7.59e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CREBBP—urinary bladder cancer	1.2e-05	7.58e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—IGF1—urinary bladder cancer	1.19e-05	7.48e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—KRAS—urinary bladder cancer	1.16e-05	7.34e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1.14e-05	7.18e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—RHOA—urinary bladder cancer	1.09e-05	6.86e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—EGFR—urinary bladder cancer	1.08e-05	6.8e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.05e-05	6.65e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.05e-05	6.65e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.05e-05	6.61e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—TP53—urinary bladder cancer	1.03e-05	6.52e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.02e-05	6.45e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—KRAS—urinary bladder cancer	1.02e-05	6.43e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.01e-05	6.35e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—ERBB2—urinary bladder cancer	1.01e-05	6.35e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—HRAS—urinary bladder cancer	9.9e-06	6.24e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—TYMP—urinary bladder cancer	9.62e-06	6.07e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CXCL8—urinary bladder cancer	9.55e-06	6.02e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—IL2—urinary bladder cancer	9.12e-06	5.75e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CCND1—urinary bladder cancer	8.89e-06	5.61e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—NAT2—urinary bladder cancer	8.7e-06	5.49e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—HRAS—urinary bladder cancer	8.67e-06	5.46e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—MMP9—urinary bladder cancer	8.64e-06	5.44e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CDKN1A—urinary bladder cancer	8.6e-06	5.42e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—PTEN—urinary bladder cancer	8.58e-06	5.41e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—NQO1—urinary bladder cancer	8.5e-06	5.36e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	8.25e-06	5.2e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—EP300—urinary bladder cancer	8.19e-06	5.16e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—SRC—urinary bladder cancer	7.96e-06	5.02e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—RRM2—urinary bladder cancer	7.51e-06	4.74e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.19e-06	4.54e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—MYC—urinary bladder cancer	7.13e-06	4.5e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	7.09e-06	4.47e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—EGFR—urinary bladder cancer	6.98e-06	4.4e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—ENO2—urinary bladder cancer	6.96e-06	4.39e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	6.96e-06	4.39e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.86e-06	4.33e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	6.75e-06	4.25e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—KRAS—urinary bladder cancer	6.59e-06	4.16e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—TYMS—urinary bladder cancer	6.59e-06	4.16e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	6.52e-06	4.11e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	6.52e-06	4.11e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—GPX1—urinary bladder cancer	6.24e-06	3.93e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	6.13e-06	3.86e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—TP53—urinary bladder cancer	5.86e-06	3.69e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	5.76e-06	3.63e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—NQO1—urinary bladder cancer	5.61e-06	3.53e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—HRAS—urinary bladder cancer	5.6e-06	3.53e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	4.68e-06	2.95e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—PPARG—urinary bladder cancer	4.67e-06	2.94e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	4.49e-06	2.83e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—TYMS—urinary bladder cancer	4.35e-06	2.74e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	4.3e-06	2.71e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	4.3e-06	2.71e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—GPX1—urinary bladder cancer	4.12e-06	2.59e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	4.04e-06	2.55e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	3.8e-06	2.39e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	3.67e-06	2.32e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—PTEN—urinary bladder cancer	3.2e-06	2.02e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—PPARG—urinary bladder cancer	3.08e-06	1.94e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—EP300—urinary bladder cancer	3.06e-06	1.93e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.96e-06	1.87e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.42e-06	1.53e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.11e-06	1.33e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.01e-06	1.27e-05	CbGpPWpGaD
